Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigating the Mechanisms of Short- and Long-term Responses to IL-23 Inhibition Using Tildrakizumab in Moderate to Severe Plaque Psoriasis Using High-definition Multiomics

NCT07244744 is registered in ClinicalTrials.gov with University Hospital Schleswig-Holstein as lead sponsor.

NCT NCT07244744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07244744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigating the Mechanisms of Short- and Long-term Responses to IL-23 Inhibition Using Tildrakizumab in Moderate to Severe Plaque Psoriasis Using High-definition Multiomics
Lead sponsor
University Hospital Schleswig-Holstein
Phase
Observational
Overall status
Active, not recruiting
Start date
June 27, 2023
Completion date
April 30, 2026
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis